An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors — Stella
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(11 sites)
United States
Teva Investigational Site 12017, Los Angeles, California
Teva Investigational Site 12021, Lake Mary, Florida
Teva Investigational Site 12016, Chicago, Illinois
Teva Investigational Site 12015, Detroit, Michigan
Teva Investigational Site 12014, Huntersville, North Carolina
Teva Investigational Site 12023, Cincinnati, Ohio
Teva Investigational Site 12058, Pittsburgh, Pennsylvania
Teva Investigational Site 12019, Nashville, Tennessee
Teva Investigational Site 12018, Fairfax, Virginia
Teva Investigational Site 12025, Milwaukee, Wisconsin